Exploring Analyst Estimates for Regeneron (REGN) Q3 Earnings, Beyond Revenue and EPS

Core Insights - Analysts project Regeneron (REGN) will report quarterly earnings of $9.54 per share, reflecting a year-over-year decline of 23.4% [1] - Revenue is expected to reach $3.6 billion, down 3.3% from the same quarter last year [1] Earnings Estimates - The consensus EPS estimate has been revised downward by 2% over the past 30 days, indicating a collective reassessment by analysts [2] - Revisions to earnings estimates are significant indicators for predicting investor actions regarding the stock [3] Revenue Projections - Analysts estimate 'Revenues- Libtayo- Total' at $370.10 million, a year-over-year increase of 28.2% [5] - 'Revenues- Other Revenue' is projected at $131.84 million, reflecting a 15.5% increase from the previous year [5] - 'Revenues- Net product sales' are expected to be $1.57 billion, showing a decline of 19.3% year over year [5] Specific Product Revenues - 'Revenues- Collaboration' is estimated at $1.85 billion, indicating an 11.6% year-over-year increase [6] - 'Revenues- Eylea (Aflibercept)- US' is projected at $1.09 billion, down 28.9% from the year-ago quarter [6] - 'Revenues- Dupixent (dupilumab)- US' is expected to reach $3.40 billion, reflecting a 20.4% increase year over year [8] Market Performance - Over the past month, Regeneron shares have returned +1.3%, outperforming the Zacks S&P 500 composite's +0.2% change [8] - Currently, REGN holds a Zacks Rank 3 (Hold), suggesting its performance may align with the overall market in the near future [9]